Ursodeoxycholic acid protects neonatal rats from necrotizing enterocolitis: a biochemical, histopathological, and immunohistochemical study

References

• Lin PW, Stoll BJ. Necrotising enterocolitis. Lancet. 2006;368(9543):1271–1283.
   PubMed Web of Science ®Google Scholar
• Hsueh W, Caplan MS, Qu XW, et al. Neonatal necrotizing enterocolitis: clinical considerations and pathogenetic concepts. Pediatr Dev Pathol. 2003;6(1):6–23.
   PubMed Web of Science ®Google Scholar
• Hunter CJ, Upperman JS, Ford HR, et al. Understanding the susceptibility of the premature infant to necrotizing enterocolitis (NEC). Pediatr Res. 2008;63(2):117–123.
   PubMed Web of Science ®Google Scholar
• Edelson MB, Bagwell CE, Rozycki HJ. Circulating pro- and counterinflammatory cytokine levels and severity in necrotizing enterocolitis. Pediatrics. 1999;103(4 Pt 1):766–771.
   PubMed Web of Science ®Google Scholar
• Caplan MS, Simon D, Jilling T. The role of PAF, TLR, and the inflammatory response in neonatal necrotizing enterocolitis. Semin Pediatr Surg. 2005;14(3):145–151.
   PubMedGoogle Scholar
• Nanthakumar NN, Fusunyan RD, Sanderson I, et al. Inflammation in the developing human intestine: a possible pathophysiologic contribution to necrotizing enterocolitis. Proc Natl Acad Sci USA. 2000;97(11):6043–6048.
   PubMed Web of Science ®Google Scholar
• Frost BL, Caplan MS. Necrotizing enterocolitis: pathophysiology, platelet-activating factor, and probiotics. Semin Pediatr Surg. 2013;22(2):88–93.
   PubMed Web of Science ®Google Scholar
• Tonin F, Arends IWCE. Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review. Beilstein J Org Chem. 2018;14:470–483.
   PubMed Web of Science ®Google Scholar
• Deneau M, Perito E, Ricciuto A, et al. Ursodeoxycholic acid therapy in pediatric primary sclerosing cholangitis: predictors of gamma glutamyltransferase normalization and favorable clinical course. J Pediatr. 2019;209:92–92.
   PubMed Web of Science ®Google Scholar
• Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology. 2002;36(3):525–531.
   PubMed Web of Science ®Google Scholar
• Angulo P. Use of ursodeoxycholic acid in patients with liver disease. Curr Gastroenterol Rep. 2002;4(1):37–44.
   PubMedGoogle Scholar
• Amaral JD, Viana RJ, Ramalho RM, et al. Bile acids: regulation of apoptosis by ursodeoxycholic acid. J Lipid Res. 2009;50(9):1721–1734.
   PubMed Web of Science ®Google Scholar
• Mitsuyoshi H, Nakashima T, Sumida Y, et al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun. 1999;263(2):537–542.
   PubMed Web of Science ®Google Scholar
• Eaton JE, Silveira MG, Pardi DS, et al. High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol. 2011;106(9):1638–1645.
   PubMed Web of Science ®Google Scholar
• Lloyd-Still JD, Beno DWA, Uhing MR, et al. Ursodeoxycholic acid ameliorates ibuprofen-induced enteropathy in the rat. J Pediatr Gastroenterol Nutr. 2001;32(3):270–273.
   PubMed Web of Science ®Google Scholar
• Bernardes-Silva CF, Damiao AOMC, Sipahi AM, et al. Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress. Dig Dis Sci. 2004;49(10):1569–1574.
   PubMed Web of Science ®Google Scholar
• Goossens JF, Bailly C. Ursodeoxycholic acid and cancer: from chemoprevention to chemotherapy. Pharmacol Therapeut. 2019;203:107396. DOI:https://doi.org/10.1016/j.pharmthera.2019.107396. PMID: 31356908.
   Google Scholar
• Caplan MS, Hedlund E, Adler L, et al. Role of asphyxia and feeding in a neonatal rat model of necrotizing enterocolitis. Pediatr Pathol. 1994;14(6):1017–1028.
   PubMed Web of Science ®Google Scholar
• Ortak H, Cayli S, Ocakli S, et al. Age-related changes of aquaporin expression patterns in the postnatal rat retina. Acta Histochem. 2013;115(4):382–388.
   PubMed Web of Science ®Google Scholar
• Yurttutan S, Ozdemir R, Canpolat FE, et al. Protective effects of colchicine in an experimental model of necrotizing enterocolitis in neonatal rats. J Surg Res. 2013;183(1):156–162.
   PubMed Web of Science ®Google Scholar
• Li LQ, Wu B, Gao XX, et al. Role of probiotics in the prevention of neonatal necrotizing enterocolitis: a case-control study. Chinese J Contemporary Pediatr. 2006;8(6):464–466.
   Google Scholar
• Shah PS, Shah VS, Kelly LE. Arginine supplementation for prevention of necrotising enterocolitis in preterm infants. Cochrane Database Syst Rev. 2017;4:CD004339.
   PubMed Web of Science ®Google Scholar
• Canpolat FE, Yurdakok M, Ersin SC. Effects of enterally administered surfactant in a rat model of necrotizing enterocolitis. Neonatology. 2012;102(1):53–58.
   PubMed Web of Science ®Google Scholar
• Cigsar EB, Karadag CA, Tanik C, et al. The protective effects of sesamol in a neonatal rat model of necrotizing enterocolitis. J Matern Fetal Neonatal Med. 2020;33(6):889–894.
   PubMed Web of Science ®Google Scholar
• Lapenna D, Ciofani G, Festi D, et al. Antioxidant properties of ursodeoxycholic acid [Research Support, Non-U.S. Gov't]. Biochem Pharmacol. 2002;64(11):1661–1667.
   PubMed Web of Science ®Google Scholar
• Martinez-Moya P, Romero-Calvo I, Requena P, et al. Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis. Int Immunopharmacol. 2013;15(2):372–380.
   PubMed Web of Science ®Google Scholar
• Ward JBJ, Lajczak NK, Kelly OB, et al. Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. Am J Physiol Gastrointest Liver Physiol. 2017;312(6):G550–G558.
   PubMed Web of Science ®Google Scholar
• Achufusi TGO, Mahabadi N. Ursodeoxycholic acid. Treasure Island (FL): StatPearls; 2020.
   Google Scholar
• Golden JM, Escobar OH, Nguyen MVL, et al. Ursodeoxycholic acid protects against intestinal barrier breakdown by promoting enterocyte migration via EGFR- and COX-2-dependent mechanisms. Am J Physiol Gastrointest Liver Physiol. 2018;315(2):G259–G271.
   PubMed Web of Science ®Google Scholar
• Laukens D, Devisscher L, Van den Bossche L, et al. Tauroursodeoxycholic acid inhibits experimental colitis by preventing early intestinal epithelial cell death [Research Support, Non-U.S. Gov't]. Lab Invest. 2014;94(12):1419–1430.
   PubMed Web of Science ®Google Scholar
• Rodrigues CMP, Steer CJ. The therapeutic effects of ursodeoxycholic acid as an anti-apoptotic agent. Expert Opin Investig Drugs. 2001;10(7):1243–1253.
   PubMed Web of Science ®Google Scholar
• Vang S, Longley K, Steer CJ, et al. The unexpected uses of urso- and tauroursodeoxycholic acid in the treatment of non-liver diseases. Glob Adv Health Med. 2014;3(3):58–69.
   PubMedGoogle Scholar
• Cohen GM. Caspases: the executioners of apoptosis. Biochem J. 1997;326(1):1–16.
   PubMed Web of Science ®Google Scholar
• Benz C, Angermuller S, Tox U, et al. Effect of tauroursodeoxycholic acid on bile-acid-induced apoptosis and cytolysis in rat hepatocytes. J Hepatol. 1998;28(1):99–106.
   PubMed Web of Science ®Google Scholar
• Benz C, Angermuller S, Otto G, et al. Effect of tauroursodeoxycholic acid on bile acid-induced apoptosis in primary human hepatocytes. Eur J Clin Invest. 2000;30(3):203–209.
   PubMed Web of Science ®Google Scholar
• Li P, Fu D, Sheng Q, et al. TUDCA attenuates intestinal injury and inhibits endoplasmic reticulum stress-mediated intestinal cell apoptosis in necrotizing enterocolitis. Int Immunopharmacol. 2019;74:105665.
   PubMed Web of Science ®Google Scholar
• Hackam D, Caplan M. Necrotizing enterocolitis: pathophysiology from a historical context. Semin Pediatr Surg. 2018;27(1):11–18.
   PubMed Web of Science ®Google Scholar
• Caplan MS, Lickerman M, Adler L, et al. The role of recombinant platelet-activating factor acetylhydrolase in a neonatal rat model of necrotizing enterocolitis. Pediatr Res. 1997;42(6):779–783.
   PubMed Web of Science ®Google Scholar
• MacKendrick W, Hill N, Hsueh W, et al. Increase in plasma platelet-activating factor levels in enterally fed preterm infants. Biol Neonate. 1993;64(2-3):89–95.
   PubMedGoogle Scholar
• Caplan MS, Sun XM, Hsueh W. Hypoxia causes ischemic bowel necrosis in rats: the role of platelet-activating factor (PAF-acether). Gastroenterology. 1990;99(4):979–986.
   PubMed Web of Science ®Google Scholar
• Caplan MS, Hsueh W. Necrotizing enterocolitis: role of platelet activating factor, endotoxin, and tumor necrosis factor. J Pediatr. 1990;117(1 Pt 2):S47–S51.
   PubMed Web of Science ®Google Scholar
• Caplan MS, Hedlund E, Adler L, et al. The platelet-activating factor receptor antagonist WEB 2170 prevents neonatal necrotizing enterocolitis in rats. J Pediatr Gastroenterol Nutr. 1997;24(3):296–301.
   PubMed Web of Science ®Google Scholar
• Hsueh W, Gonzalez-Crussi F, Arroyave JL, et al. Platelet activating factor-induced ischemic bowel necrosis: the effect of PAF antagonists. Eur J Pharmacol. 1986;123(1):79–83.
   PubMed Web of Science ®Google Scholar
• Furukawa M, Lee EL, Johnston JM. Platelet-activating factor-induced ischemic bowel necrosis: the effect of platelet-activating factor acetylhydrolase. Pediatr Res. 1993;34(2):237–241.
   PubMed Web of Science ®Google Scholar
• Aydemir C, Dilli D, Oguz SS, et al. Serum intestinal fatty acid binding protein level for early diagnosis and prediction of severity of necrotizing enterocolitis. Early Hum Dev. 2011;87(10):659–661.
   PubMed Web of Science ®Google Scholar
• Goncalves FLL, Soares LMM, Figueira RL, et al. Evaluation of the expression of I-FABP and L-FABP in a necrotizing enterocolitis model after the use of Lactobacillus acidophilus. J Pediatr Surg. 2015;50(4):543–549.
   PubMed Web of Science ®Google Scholar